Ph.D. Sir Marc Feldmann - 28 Dec 2023 Form 4 Insider Report for 180 Life Sciences Corp. (ATNF)

Reporting relationship: Director
Issuer ticker: ATNF
Reported as of: 28 Dec 2023
Net transaction value: $0
SEC form: 4
Accepted by SEC: 28 Dec 2023, 18:42:49 UTC
Prior SEC filing: 18 Dec 2023
Source filing: View source filing
Reporting owner signature: /s/ Sir Marc Feldmann, Ph.D.

Key filing fact

Ph.D. Sir Marc Feldmann filed Form 4 for 180 Life Sciences Corp. (ATNF) on 28 Dec 2023.

Key facts

This page summarizes Ph.D. Sir Marc Feldmann's Form 4 filing for 180 Life Sciences Corp. (ATNF).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 28 Dec 2023, 18:42.

Change

Previous filing in this sequence was filed on 18 Dec 2023.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

ATNF transaction

Common Stock

Award

Transaction value: $0
Shares: +135,377
Change %: +117%
Price: $0.000000
Shares after: 250,874
Date: 28 Dec 2023
Ownership: Direct
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

Granted to the Reporting Person pursuant to the Issuer's equity compensation plans in consideration for services rendered. Exempt from Section 16(b) of the Securities Exchange Act of 1934 under Rule 16b-3.